Skip to content
Screener

Ultragenyx Pharmaceutical RARE Q2 2026 earnings

Reported August 4, 2026 · After market close

Revenue$214.0MBeat by $30.9M
EPS-$0.90Beat by $0.32
Revenue estimate$183.1M
EPS estimate-$1.22
“As we look to the second half of the year, we are entering a transformative period with multiple important catalysts. We are ready to launch two gene therapy products and are preparing for a pivotal Phase 3 GTX-102 data readout in Angelman syndrome. This puts us in position to broaden our patient impact with sustained growth in the years to come.”
Emil D. Kakkis

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$182.9M
EPS estimate-$0.65

Financials

Q2 2026

Income statement

See full
Revenue$214.0M+28.1%
Operating income-$75.0M+30.6%
Net income-$92.0M+20.0%
EPS (diluted)-$0.90+23.1%

Balance sheet

See full
Cash & equivalents$125.0M-29.0%
Total equity-$291.0M-293%
Total assets$1.3B-3.2%

Cash flow

See full
Operating cash flow-$97.0M+11.0%
CapEx$1.0M-66.7%
Free cash flow-$98.0M+12.5%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$1.29B-54.1%
P/S1.8×-2.8×

Profitability

See full
Operating margin-73.6%-7.3pp
Net margin-81.7%-4.9pp
FCF margin-68.2%-1.7pp

Returns & leverage

See full
Current ratio1.7×-0.7×

Segments

By geography

See full
North America$121.0M+17.5%
Latin America$51.0M+54.5%
EMEA$35.0M+29.6%
Asia Pacific$7.0M+75.0%

By product

See full
Collaboration And Royalty$156.0M+28.9%
Royalty$102.0M+18.6%
Non Cash Royalty$35.0M+12.9%

FAQ

When did Ultragenyx Pharmaceutical report Q2 2026 earnings?
Ultragenyx Pharmaceutical (RARE) reported Q2 2026 earnings on August 4, 2026 after market close.
What were Ultragenyx Pharmaceutical's Q2 2026 revenue and EPS?
Ultragenyx Pharmaceutical reported revenue of $214.0M and eps of $-0.90 for Q2 2026.
Did Ultragenyx Pharmaceutical beat estimates in Q2 2026?
Revenue beat the consensus estimate of $183.1M by $30.9M. EPS beat the consensus estimate of $-1.22 by $0.32.
How did Ultragenyx Pharmaceutical's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 28.5% from $166.5M a year earlier and eps grew 23.1% from $-1.17.
Where can I find Ultragenyx Pharmaceutical's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-332802) and the 10-Q periodic report (0001193125-26-333233) directly on SEC EDGAR. The filing index links above go to sec.gov.